The purpose of Core A is to oversee the administrative responsibilities of the various laboratory studies outlined in the Projects 1, 2 and 3 in this P01. Core A will provide high-level organizational support for the Projects, including provision of necessary resources, fiscal oversight, adherence to institutional and NIH guidelines/regulations. Core A will further coordinate regular joint meetings to disseminate results, discuss scientific challenges, and discover innovative solutions to advance the science. Core A will serve to integrate scientific efforts for sample collection and clinical factor analysis within and between Projects through the (i) coordination of sample tracking and (ii) the retrieval and data collection for all 3 Projects with institutions both within and outside of DFCI. Core A also has responsibility for the submission/maintenance of regulatory documents related to samples. Core A will further promote the rapid dissemination of significant research findings to the scientific community. These activities will serve to enhance the integration of the rich scientific efforts within and between Projects, and foster the translation of findings to the patient care setting; and conversely, the initiation of laboratory studies stemming from clinical observations and tissue samples obtained in all 3 projects. Altogether, this central resource for the Projects will enhance interactions among the investigative teams to further the translational goals and vision of this Program for integrating genomic, functional and clinical information of CLL patients.

Public Health Relevance

Core A will oversee the administrative responsibilities of the various laboratory studies outlined in the three Projects, by providing high-level organizational support for the Projects. These include provision of necessary resources, fiscal oversight, adherence to institutional and NIH guidelines/regulations, and the coordination of regular joint meetings to disseminate results, discuss scientific challenges, and discover innovative solutions to advance the science. Core A will further promote the rapid dissemination of significant research findings to the scientific community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA206978-03
Application #
9548933
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
Ten Hacken, Elisa; Valentin, Rebecca; Regis, Fara Faye D et al. (2018) Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3:
Lampson, Benjamin L; Brown, Jennifer R (2018) Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol 11:185-194
Wang, Lili; Livak, Kenneth J; Wu, Catherine J (2018) High-dimension single-cell analysis applied to cancer. Mol Aspects Med 59:70-84
Landau, Dan A; Sun, Clare; Rosebrock, Daniel et al. (2017) The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun 8:2185
Compagno, Mara; Wang, Qi; Pighi, Chiara et al. (2017) Phosphatidylinositol 3-kinase ? blockade increases genomic instability in B cells. Nature 542:489-493
Ten Hacken, Elisa; Guièze, Romain; Wu, Catherine J (2017) SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell 32:716-716.e1
Murphy, E J; Neuberg, D S; Rassenti, L Z et al. (2017) Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia 31:1348-1354
Deng, J; Isik, E; Fernandes, S M et al. (2017) Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31:2075-2084
Tiao, G; Improgo, M R; Kasar, S et al. (2017) Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia 31:2244-2247
Wang, Lili; Fan, Jean; Francis, Joshua M et al. (2017) Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res 27:1300-1311

Showing the most recent 10 out of 11 publications